Why Is HUTCHMED Stock Soaring Thursday?
HUTCHMED stock jumps on a $1.3B GSK deal for its cancer drug HMPL-A830. Learn the financial terms and key global rights split.
Read original at benzingaStocks · News reference
Sensodyne Maker Haleon Leverages Eye-Level Shelf Placement To Outpace Rivals-Report
Haleon gains US market share at Walmart and Target by securing eye-level shelf placement with aggressive promotional strategies.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Does Moderna's mRNA Flu Shot Face a New Challenge From GSK?
Moderna secured FDA approval for mFlusiva, the first mRNA-based seasonal flu vaccine, establishing a foothold in the multibillion-dollar flu vaccine market. However, GSK announced plans to advance its own mRNA flu vaccine into phase III trials, which targets two viral proteins (HA and NA) and showed superior immune responses in phase II studies. While GSK's vaccine is still years away from market approval, it could pose a competitive challenge to Moderna's mFlusiva, which currently targets only HA like traditional flu vaccines.
Read original at zacks-investment-researchCan Bixlenvo Unlock New Growth for Gilead's HIV Business?
Gilead Sciences received FDA approval for Bixlenvo, a once-daily single-tablet HIV regimen for virologically suppressed adults unable to take current treatments. The company raised its 2026 HIV sales growth outlook to 9-10%, driven by flagship drugs Biktarvy, Descovy, and the rapidly growing Yeztugo injectable PrEP. Bixlenvo and Gilead's expanding lenacapavir pipeline offer additional growth opportunities in HIV treatment and prevention.
Read original at zacks-investment-research'Haleon Says It Negotiated Better Walmart, Target Shelf Space Via U.S. Price Deals; Haleon Says Improved Shelf Positions Are Driving U.S. Market Share' - Reuters Exclusive
Read original at benzingaLululemon’s Margin Problem Could Spell Trouble for These ETFs
Lululemon's margin pressure raises concerns for consumer ETFs as weak sales, tariffs, and competition test retail profitability.
Read original at benzingaTarget Expands Beauty Strategy With 600-Store Studio Rollout
Target is expanding its beauty segment with the launch of Beauty Studio in over 600 stores on September 10, featuring 1,600 products from 90 prestige and global brands. Beauty net sales grew to $3.64B from $3.40B year-over-year, demonstrating strong momentum in this key strategic category.
Read original at zacks-investment-research